Clinical Trial Update: Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2, placebo-controlled dose-response study of rivoglitazone in type 2 diabetes has completed, according to an update from the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Rivoglitazone (rivoglitazone)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED